Compare SFWL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFWL | MCRB |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 71.0M |
| IPO Year | 2021 | 2015 |
| Metric | SFWL | MCRB |
|---|---|---|
| Price | $0.80 | $5.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 15.8K | ★ 131.7K |
| Earning Date | 03-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $5.00 |
| 52 Week High | $1.29 | $29.98 |
| Indicator | SFWL | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 34.03 |
| Support Level | $0.59 | N/A |
| Resistance Level | $1.03 | $9.53 |
| Average True Range (ATR) | 0.08 | 0.57 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 63.70 | 6.77 |
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.